ADMP Adamis Pharmaceuticals Corporation

+0.04  (+1%)
Previous Close 3.13
Open 3.16
Price To Book 2.6
Market Cap 149913605
Shares 47,291,358
Volume 267,877
Short Ratio
Av. Daily Volume 424,446

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 planned for December 2018.
FDA Approval announced September 27, 2018.
Symjepi - low dose
NDA filing announced December 31, 2018.
APC-6000 Naloxone Pre-Filled Syringe
Opioid overdose
NDA filing announced December 28, 2018.
APC-8000 (sublingual tadalafil)
Erectile dysfunction

Latest News

  1. Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
  2. Is Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Excessively Paying Its CEO?
  3. The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
  4. Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept
  5. Adamis stock surges on release of EpiPen alternative
  6. Adamis’ Commercial Partner Launches SYMJEPI™ (epinephrine) in the US
  7. Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
  8. Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James
  9. Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
  10. 4 Pharma Stocks Gaining Speed on Monday (12/31/18)
  11. Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet
  12. Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%
  13. Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
  14. Novartis to launch Adamis' EpiPen rival in U.S. next year
  15. Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI
  16. Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
  17. Adamis Pharmaceuticals (ADMP) Reports Q3 Loss, Lags Revenue Estimates
  18. Adamis: 3Q Earnings Snapshot
  19. Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19582787
  2. 8-K - Current report 19568889
  3. S-8 - Securities to be offered to employees in employee benefit plans 19543202
  4. 8-K - Current report 19533723
  5. CT ORDER - Confidential treatment order 181240517
  6. 8-K - Current report 181223640
  7. 8-K - Current report 181184347
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173287
  9. 8-K - Current report 181092599
  10. 8-K - Current report 181056737